Literature DB >> 15159137

GABAA receptors modulate cannabinoid-evoked hypothermia.

S M Rawls1, R J Tallarida, D A Kon, E B Geller, Martin W Adler.   

Abstract

Cannabinoids evoke hypothermia by stimulating central CB(1) receptors. GABA induces hypothermia via GABA(A) or GABA(B) receptor activation. CB(1) receptor activation increases GABA release in the hypothalamus, a central locus for thermoregulation, suggesting that cannabinoid and GABA systems may be functionally linked in body temperature regulation. We investigated whether GABA receptors modulate the hypothermic actions of [4,5-dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6H-pyrrolo[3,2,1ij]quinolin-6-one] (WIN 55212-2), a selective cannabinoid agonist, in male Sprague-Dawley rats. WIN 55212-2 (2.5 mg/kg im) produced a rapid hypothermia that peaked 45-90 min postinjection. The hypothermia was attenuated by bicuculline (2 mg/kg ip), a GABA(A) antagonist. However, SCH 50911 (1-10 mg/kg ip), a GABA(B) blocker, did not antagonize the hypothermia. Neither bicuculline (2 mg/kg) nor SCH 50911 (10 mg/kg) by itself altered body temperature. We also investigated a possible role for CB(1) receptors in GABA-generated hypothermia. Muscimol (2.5 mg/kg ip), a GABA(A) agonist, or baclofen (5 mg/kg ip), a GABA(B) agonist, evoked a significant hypothermia. Blockade of CB(1) receptors with SR141716A (2.5 mg/kg im) did not antagonize muscimol- or baclofen-induced hypothermia, indicating that GABA-evoked hypothermia does not contain a CB(1)-sensitive component. Our results implicate GABA(A) receptors in the hypothermic actions of cannabinoids and provide further evidence of a functional link between cannabinoid and GABA systems.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15159137     DOI: 10.1016/j.pbb.2004.02.006

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  7 in total

1.  Corticosteroid dependent and independent effects of a cannabinoid agonist on core temperature, motor activity, and prepulse inhibition of the acoustic startle reflex in Wistar rats.

Authors:  Avdesh Avdesh; Vincent Cornelisse; Mathew Thomas Martin-Iverson
Journal:  Psychopharmacology (Berl)       Date:  2011-09-27       Impact factor: 4.530

2.  Endocannabinoid Catabolic Enzymes Play Differential Roles in Thermal Homeostasis in Response to Environmental or Immune Challenge.

Authors:  Sara R Nass; Jonathan Z Long; Joel E Schlosburg; Benjamin F Cravatt; Aron H Lichtman; Steven G Kinsey
Journal:  J Neuroimmune Pharmacol       Date:  2015-02-27       Impact factor: 4.147

3.  Substitution profile of Delta9-tetrahydrocannabinol, triazolam, hydromorphone, and methylphenidate in humans discriminating Delta9-tetrahydrocannabinol.

Authors:  Joshua A Lile; Thomas H Kelly; David J Pinsky; Lon R Hays
Journal:  Psychopharmacology (Berl)       Date:  2008-11-19       Impact factor: 4.530

Review 4.  Effects of opioids, cannabinoids, and vanilloids on body temperature.

Authors:  Scott M Rawls; Khalid Benamar
Journal:  Front Biosci (Schol Ed)       Date:  2011-06-01

5.  Long-Term Low-Dose Delta-9-Tetrahydrocannbinol (THC) Administration to Simian Immunodeficiency Virus (SIV) Infected Rhesus Macaques Stimulates the Release of Bioactive Blood Extracellular Vesicles (EVs) that Induce Divergent Structural Adaptations and Signaling Cues.

Authors:  Yuan Lyu; Steven Kopcho; Mahesh Mohan; Chioma M Okeoma
Journal:  Cells       Date:  2020-10-06       Impact factor: 6.600

6.  Decursinol-mediated antinociception and anti-allodynia in acute and neuropathic pain models in male mice: Tolerance and receptor profiling.

Authors:  LaTaijah C Crawford; Sangyub Kim; Deepkamal Karelia; Diana E Sepulveda; Daniel J Morgan; Junxuan Lü; Angela N Henderson-Redmond
Journal:  Front Pharmacol       Date:  2022-09-29       Impact factor: 5.988

7.  Molecular and cellular pathways as a target of therapeutic hypothermia: pharmacological aspect.

Authors:  Hyung Soo Han; Jaechan Park; Jong-Heon Kim; Kyoungho Suk
Journal:  Curr Neuropharmacol       Date:  2012-03       Impact factor: 7.363

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.